Unternehmensübersicht
Evolent Health, Inc. operates as a provider of specialty care management services within the United States, focusing specifically on oncology, cardiology, and musculoskeletal markets through its subsidiary. The company functions within the broader healthcare sector, specifically categorized under health information services, where it delivers an integrated value-based care platform designed for health plan administration and management alongside administrative support services. With a market capitalization of $285.79M, annual revenue of $1.88B, and an employee base of 4200, the firm represents a mid-sized entity within the competitive landscape of health information services. These valuation and revenue metrics suggest that while the company maintains a significant operational footprint with substantial annual revenue generation, its market cap reflects a valuation that is sensitive to current profitability challenges and market sentiment regarding its long-term growth trajectory in the specialized care management niche.
Finanzielle Gesundheit
The company reported revenue of $1.88B over the trailing twelve months, yet recorded a net income of $-579,401,024 and an EBITDA of $88.22M, revealing a significant divergence between top-line performance and bottom-line profitability that indicates a highly leveraged cost structure or substantial one-time expenses impacting net earnings. Despite the negative net income, the generation of $98.41M in free cash flow demonstrates that the business retains operational liquidity and possesses a degree of financial flexibility to fund operations or reduce debt obligations independent of accounting earnings. Profitability analysis shows a gross margin of 21.3%, an operating margin of -2.1%, and a profit margin of -28.5%, where the stark contrast between positive gross margins and deeply negative operating and profit margins highlights severe cost inefficiencies or high operating expenses that are eroding the value generated from sales. On the balance sheet, the company holds $151.86M in cash against total debt of $989.70M, resulting in a debt-to-equity ratio of 238.37, which characterizes the balance sheet as highly leveraged and potentially vulnerable to interest rate fluctuations or credit tightening. Liquidity assessment via the current ratio of 1.31 suggests that the company maintains a conservative approach to short-term obligations, possessing sufficient current assets to cover current liabilities, though the buffer is relatively narrow given the heavy debt load. Finally, the return on equity stands at -66.5% and the return on assets at -0.1%, metrics that indicate management has not yet achieved positive capital efficiency and are currently destroying shareholder value rather than generating returns on the invested capital base.
Bewertungsanalyse
Valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is 5.80, implying that the market is pricing in a significant turnaround in future earnings trajectory rather than current profitability. The price-to-book ratio of 0.69 indicates that the stock trades at a discount to its book value, suggesting that the market does not currently assign a premium to the company's tangible assets or future growth potential. Alternative valuation measures further reflect this discounted stance, with a price-to-sales ratio of 0.15 and an EV/EBITDA of 12.74, suggesting that despite the low multiple relative to sales, the earnings-based valuation remains elevated relative to the negative earnings reality. Price action analysis shows a 52-week high of $12.06 and a 52-week low of $2.10, meaning the current market price sits significantly below the historical high, reflecting the substantial downside volatility experienced over the last year. The beta value of 0.37 indicates that the stock exhibits low volatility relative to the broader market, moving with much less intensity than the general equity index, which may offer some downside protection but also limits upside potential during market rallies.
Growth & Income
Growth metrics reveal a challenging environment with revenue growth year-over-year at -27.5% and earnings growth listed as N/A due to the absence of positive earnings to track, indicating that the company is currently contracting rather than expanding its top line and profitability simultaneously. As the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, all available cash flow is theoretically available for reinvestment into operations, debt repayment, or potential acquisitions rather than distribution to shareholders. The absence of a dividend policy combined with negative earnings growth suggests the company is in a preservation mode, prioritizing liquidity and solvency over income generation for investors. Consequently, the overall growth and income profile is characterized by a contraction in revenue, a lack of dividend income, and a heavy reliance on operational cash flow to sustain a highly leveraged balance sheet in the absence of profit generation.